All In Biotech

Drug Trial Radar · NCT06890611

A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants

A Phase 1, Relative Bioavailability Study of Bimagrumab (LY3985863) Test and Reference Materials, and Bimagrumab Test Material Coadministration and Coformulation With Tirzepatide (LY900042), in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Oct 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 125 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

125

Actual

Start

Mar 25, 2025

Primary completion

Sep 26, 2025

Study completion Sep 26, 2025

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Mar 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide. Participation in the study will last about 4.5 months, including screening and follow-up.

Conditions

  • Healthy

Interventions

  • BimagrumabDrug

    Administered SC

  • TirzepatideDrug

    Administered SC

  • Bimagrumab + Tirzepatide CoformulationDrug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Bimagrumab Test MaterialTime frame: Predose through Week 13
  2. PK: Cmax of Bimagrumab Reference MaterialTime frame: Predose through Week 13
  3. PK: Cmax of Bimagrumab Coadministered with TirzepatideTime frame: Predose through Week 13
  4. PK: Cmax of Tirzepatide Coadministered with BimagrumabTime frame: Predose through Week 16
  5. PK: Cmax of Bimagrumab Coformulated with TirzepatideTime frame: Predose through Week 16
  6. PK: Cmax of Tirzepatide Coformulated with BimagrumabTime frame: Predose through Week 16
  7. PK: Area Under the Curve from Zero to Infinity AUC (AUC(0-∞)) of Bimagrumab Test MaterialTime frame: Predose through Week 13
  8. PK: AUC(0-∞) of Bimagrumab Reference MaterialTime frame: Predose through Week 13
  9. PK: AUC(0-∞) of Bimagrumab Coadministered with TirzepatideTime frame: Predose through Week 13
  10. PK: AUC(0-∞) of Tirzepatide Coadministered with BimagrumabTime frame: Predose through Week 16
  11. PK: AUC(0-∞) of Bimagrumab Coformulated with TirzepatideTime frame: Predose through Week 16
  12. PK: AUC(0-∞) of Tirzepatide Coformulated with BimagrumabTime frame: Predose through Week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fortrea Clinical Research Unit

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.